PD-0332991(Palbociclib, PF-0332991, PF-332991)Request
Price of PD-0332991(Palbociclib, PF-0332991, PF-332991)
please inquire via
or Fax: 1-201-884-1288(USA Fax#)
We match the lowest price on market.
An orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation.
Storage Conditions :Room temperature, or -20ºC for 2 year.
1.Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Oncogene 29, 4018-4032 (15 July 2010) | doi:10.1038/onc.2010.154